Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499

Eli Lilly And Co (NYSE:LLY) announced on Monday that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—would soon be available in single-dose vials for $499 per month through LillyDirect’s Self Pay Pharmacy Solutions and the Zepbound Self Pay Journey Program.

Healthcare providers can begin prescribing the 12.5 mg and 15 mg vials on July 7; shipments to patients will begin in early August.

With the addition of these doses, every strength of Zepbound vial will be available for $499/month or less ($349 for the 2.5 mg starter dose) to any eligible adult with obesity and a valid prescription, regardless of insurance.

Also Read: Eli Lilly’s Obesity Drug Success Spurs Japanese Biotech’s Anti-Muscle-Wasting Combo Therapy

Zepbound is an injectable prescription medicine that may help adults with obesity or some overweight adults with weight-related medical problems to lose excess body weight and keep the weight off.

It may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.

Patients with obesity who choose to self-pay will ...